Abstract:In an effort to overcome the nasal mucus barrier and epithelial barrier, as well as reduce entry into the bloodstream, we designed RWrNM and DLPC-modified PLGA nanoparticles (PDR-NPs). These nanoparticles were further encapsulated with dexamethasone acetate (Dexac) to form Dexac/PDR-NPs. Transmission electron microscopy (TEM) analysis revealed their spherical shape with an outer lipid layer. Dynamic light scattering (DLS) determined their particle size to be 125.77 ± 2.01 nm, with a polydispersity index (PDI) of 0.139 ± 0.029. The experimental results demonstrate that DLPC-modified PLGA nanoparticles can effectively reduce interactions with mucin at different concentrations, decrease aggregation, and facilitate their crossing of the mucus barrier. Additionally, results from the cellular uptake assay revealed a significantly greater uptake of PDR-NPs by inflammatory RAW 264.7 cells (2.99-fold higher than that of free C6, p < 0.0001) and inflammatory HUVECs (7.20-fold higher than that of free C6, p < 0.0001). Furthermore, Dexac/PDR-NPs effectively reduced the levels of inflammatory factors nitric oxide (NO) (p < 0.001) and interleukin-6 (IL-6) (p < 0.05) in the supernatant of inflammatory RAW 264.7 cells. Intravital imaging of rats revealed that PDR-NPs had a longer residence time in inflamed nasal tissue compared to PD-NPs. Furthermore, in vivo pharmacodynamic experiments showed that Dexac/PDR-NPs effectively reduced the symptoms of nasal inflammation, lowered the pH of nasal secretions, decreased serum inflammatory factor levels (TNF-α and IL-6), and reduced nasal mucosal inflammatory factor levels (IL-1β), while also reducing the degree of inflammation in the nasal mucosa. Both cytotoxicity assays and in vivo results indicate that PDR-NPs have a good safety profile. PDR-NPs not only overcome the nasal mucus barrier but also reduce the systemic toxicities associated with drug entry into the circulation by enhancing the targeting of inflammatory macrophages and inflammatory vascular endothelial cells. PDR-NPs allow for an "open sources and cut costs" treatment strategy to increase drug retention in the inflamed nasal tissues, reducing toxicity and increasing efficacy. In conclusion, PDR-NPs can be a promising drug delivery system for the local treatment of acute rhinosinusitis.

Chitosan Hydrogel Doped with PEG-PLA Nanoparticles for the Local Delivery of Mirna-146A to Treat Allergic Rhinitis

Nasal Adaptive Chitosan-Based Nano-Vehicles for Anti-Allergic Drug Delivery

Preparation and in vitro characterization of thermosensitive and mucoadhesive hydrogels for nasal delivery of phenylephrine hydrochloride

Intranasal Morphology Transformation Nanomedicines for Long-Term Intervention of Allergic Rhinitis

Construction of PLGA nanoparticles modified with RWrNM and DLPC and their application in acute rhinosinusitis

Preparation,Characterization of Nasal Mucoadhesive Microspheres of Recombinant Human Interleukin-2 Based on Chitosan and Their Effect on Allergic Rhinitis in Rabbits

Preparation and Evaluation of Intranasal in Situ Gel of Bupleuri Radix Volatile Oil and Baicalin

Facile fabrication of diatomite biosilica-based nasal drug delivery vehicle for enhanced treatment of allergic rhinitis

[Applying Chitosan-Modified Nanoemulsion in Nasal Vaccine Delivery].

NGR-modified PEG-PLGA micelles containing Shikonin enhance targeting of dendritic cells for therapy of allergic rhinitis

Chitosan-centered Nanosystems As Sustained Therapeutics for Allergic Rhinitis Intervention: Inhibition of Histamine-Induced Cascades

An Inhalable Beta(2)-Adrenoceptor Ligand-Directed Guanidinylated Chitosan Carrier For Targeted Delivery Of Sirna To Lung

[Preparation of Cangyi nanoemulsion in situ gel and drug release mechanism of nasal mucosa in vitro]

A Supramolecular Assembly of EGCG for Long-Term Treatment of Allergic Rhinitis

Polymeric nanoparticles for the delivery of miRNA to treat Chronic Obstructive Pulmonary Disease (COPD)

Physico-Chemical and In Vitro Characterization of Chitosan-Based Microspheres Intended for Nasal Administration

In situ gel based on gellan gum as new carrier for nasal administration of mometasone furoate.

Preparation of Mpeg2000-Pla-modified Xingnaojing Microemulsion and Evaluation in Mucosal Irritation.

Ionic liquid-based in situ dynamically self-assembled cationic lipid nanocomplexes (CLNs) for enhanced intranasal siRNA delivery

ROS responsive hydrogel for inhibition of MUC5AC against allergic rhinitis: A new delivery strategy for Ipratropium Bromide

Design and Characterization of a New Formulation for the Delivery of COVID-19-mRNA Vaccine to the Nasal Mucosa